Evgen Pharma PLC is a clinical-stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases.
The company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.
Evgen Pharma's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the company's new enteric-coated tablet formulation.